- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07251972
Comparison of Two Methods of Immunoprophylaxis Against RSV in Term Newborns (Abrystus)
Comparison of Two Methods of Immunoprophylaxis Against RSV in Term Newborns in a Level 3 Maternity Unit During Winter 2025-2026
Bronchiolitis is a lower respiratory tract infection, extremely common in pediatrics, and potentially serious. Bronchiolitis affects nearly 30% of infants under 2 years old each year, representing approximately 480,000 cases annually worldwide. Each year, 2 to 3% of infants under 1 year old are hospitalized for bronchiolitis. The virus primarily found worldwide and in France is RSV. Given the scale, frequency, and potential severity of the illness, several immunoprophylaxis methods have been developed.
Currently, there are two methods: the ABRYSVO vaccine, administered to pregnant women during the last month of pregnancy for immunization via the placenta through the transplacental passage of anti-RSV-A and RSV-B antibodies; or neonatal immunoprophylaxis with BEYFORTUS, which involves an intramuscular injection of the monoclonal antibody nirvesimab directly into the newborn immediately before discharge from the maternity ward during the epidemic period.
Currently, no superiority or difference has been described for either immunoprophylaxis method.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
-
Nancy, France
- Chru Nancy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- all term born neonates
Exclusion Criteria:
- postnatal transfert
- born at home or in birthing center
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bronchiolitis incidence
Time Frame: 8 months
|
Number of emergency room visits for bronchiolitis
|
8 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Infections
- Infections
- Respiratory Tract Diseases
- Lung Diseases
- Bronchial Diseases
- Lung Diseases, Obstructive
- Bronchitis
- Bronchiolitis
- Amino Acids, Peptides, and Proteins
- Proteins
- Antibodies
- Immunoglobulins
- Immunoproteins
- Blood Proteins
- Serum Globulins
- Globulins
- Antibodies, Monoclonal
Other Study ID Numbers
- 2025PI033
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchiolitis
-
Regend TherapeuticsShanghai Children's HospitalRecruitingPediatric Bronchiolitis ObliteransChina
-
Fondazione IRCCS Policlinico San Matteo di PaviaCompletedBronchiolitis Obliterans Syndrome (BOS)Italy
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedBronchiolitis Obliterans | Graft vs Host Disease | Constrictive Bronchiolitis | Bronchiolitis, Exudative | Bronchiolitis, ProliferativeUnited States
-
University Hospital, Basel, SwitzerlandRecruitingBronchiolitis Obliterans Syndrome (BOS) | Bronchiolitis Obliterans (BO)Switzerland, Saudi Arabia
-
Hillel Yaffe Medical CenterCompletedReflexology | Bronchiolitis; ChemicalIsrael
-
Seattle Children's HospitalPatient-Centered Outcomes Research Institute; Children's Hospital of PhiladelphiaRecruiting
-
NYU Langone HealthTerminatedAcute BronchiolitisUnited States
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker CochinCompletedSevere Viral BronchiolitisFrance
-
Hospices Civils de LyonCompleted
-
Guy's and St Thomas' NHS Foundation TrustCompletedAcute Viral BronchiolitisUnited Kingdom
Clinical Trials on to compare vaccine and monoclonal antibody
-
BiocadCompleted
-
European Organisation for Research and Treatment...CompletedLung CancerUnited States, Spain, Australia, United Kingdom, Belgium, Germany, Switzerland, Netherlands, Austria, New Zealand
-
BiocadCompleted
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI)CompletedLung CancerUnited States, Canada
-
European Organisation for Research and Treatment...Completed
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityZenith Institute of Medical Sciences, GuangzhouNot yet recruiting
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedSarcoma | NeuroblastomaUnited States
-
John MascarenhasTerminatedPrimary Myelofibrosis | Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Post-essential Thrombocythemia Related MyelofibrosisUnited States
-
Synermore Biologics (Suzhou) Co., Ltd.CompletedVaccine Reaction | Rabies Human | Immunisation Reaction | Zoonotic Disease | Communicable Disease TransmissionChina